Abstract PS4-10-16: Tumor Immune Microenvironment as a Predictive Marker of Neoadjuvant Pembrolizumab Combined with Chemotherapy (KEYNOTE-522 Regimen) Efficacy in Early Triple-Negative Breast Cancer